Physician profile
Serge Thys
NPI 1750391371
$7,014.49
in general payments reported to CMS, 2019-2025
25 companies · $853 in 2025
The $853 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $456 · 2021: $474 · 2022: $1,524 · 2023: $1,202 · 2024: $1,333 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.21 | 2021-2025 | Vraylar |
| Alkermes, INC. | $971.31 | 2019-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $699.36 | 2019-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $644.43 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $584.37 | 2019-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.54 | 2022-2025 | Caplyta |
| Allergan, INC. | $419.20 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $409.03 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $307.44 | 2019-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $267.60 | 2019-2025 | Rexulti |
| Corium, LLC | $181.92 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $170.13 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $80.06 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $77.00 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $75.10 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $72.38 | 2019 | |
| Idorsia Pharmaceuticals US INC | $47.72 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $43.26 | 2021-2025 | Loreev Xr |
| Indivior INC. | $34.43 | 2023 | Perseris |
| Bausch Health US, LLC | $24.21 | 2022 | |
| Livanova USA, INC. | $23.76 | 2021 | |
| Janssen Biotech, INC. | $22.74 | 2019-2023 | Symtuza |
| Sunovion Pharmaceuticals INC. | $19.68 | 2020 | |
| Acadia Pharmaceuticals INC | $17.31 | 2023 | Nuplazid |
| Hologic Sales and Service, LLC | $16.30 | 2023 | Thinprep 2000 Processor, Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Thys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.